Volume 54, Issue 3, Pages (September 1998)

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Volume 79, Pages S3-S8 (April 2011)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 65, Issue 2, Pages (February 2004)
Volume 67, Pages S1-S7 (June 2005)
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Volume 55, Issue 3, Pages (March 1999)
Cellular mechanisms of renal osteodystrophy
Renal vitamin D receptor expression and vitamin D renoprotection
Guidelines American Journal of Kidney Diseases
Volume 69, Issue 11, Pages (June 2006)
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 67, Issue 2, Pages (February 2005)
Volume 63, Pages S88-S90 (June 2003)
Section 5: Dialysis Interventions for Treatment of AKI
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Volume 76, Pages S50-S99 (August 2009)
Comorbidity and confounding in end-stage renal disease
A new era in phosphate binder therapy: What are the options?
Volume 66, Issue 3, Pages (September 2004)
Volume 70, Issue 11, Pages (December 2006)
Volume 78, Pages S33-S36 (August 2010)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 87, Issue 2, Pages (February 2015)
Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.
Volume 67, Pages S33-S36 (June 2005)
Volume 79, Issue 1, Pages (January 2011)
Volume 67, Issue 2, Pages (February 2005)
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Volume 80, Issue 5, Pages (September 2011)
Volume 63, Issue 1, Pages 1-11 (January 2003)
The calcium–phosphorus in guidelines for CKD-MBD
Volume 69, Issue 3, Pages (February 2006)
Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1  Lyndsay S. Baines, John T. Joseph,
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism 
Volume 68, Pages S24-S28 (July 2005)
Volume 68, Issue 4, Pages (October 2005)
Volume 56, Pages S31-S37 (December 1999)
Volume 70, Issue 7, Pages (October 2006)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 87, Issue 3, Pages (March 2015)
Volume 68, Issue 3, Pages (September 2005)
Volume 58, Issue 4, Pages (October 2000)
Pathogenesis of refractory secondary hyperparathyroidism
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics  William G. Goodman, L.D. Quarles 
Volume 78, Issue 4, Pages (August 2010)
A man with a hole in his penis
Volume 73, Issue 6, Pages (March 2008)
Post-transplant hypophosphatemia: Tertiary ‘Hyper-Phosphatoninism’?
Volume 79, Issue 5, Pages (March 2011)
Volume 53, Issue 5, Pages (May 1998)
Volume 56, Issue 3, Pages (September 1999)
Volume 63, Pages S79-S82 (June 2003)
Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program  Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.
Volume 60, Issue 3, Pages (September 2001)
Volume 63, Issue 2, Pages (February 2003)
Is complement a target for therapy in renal disease?
Volume 57, Issue 3, Pages (March 2000)
Recent developments in the management of secondary hyperparathyroidism
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Volume 61, Issue 4, Pages (April 2002)
Attitudes and predictive factors for live kidney donation: A comparison of live kidney donors versus nondonors  Lynn Stothers, William A. Gourlay, Li.
Volume 54, Issue 6, Pages (January 1998)
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Volume 54, Issue 3, Pages 907-914 (September 1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration  Isidro B. Salusky, Beatriz D. Kuizon, Thomas R. Belin, Jorge A. Ramirez, Barbara Gales, Gino V. Segre, William G. Goodman  Kidney International  Volume 54, Issue 3, Pages 907-914 (September 1998) DOI: 10.1046/j.1523-1755.1998.00045.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Serum total (A) and blood ionized (B) calcium levels during 12months of treatment with intermittent doses of i.p. (•) or p.o. (□) calcitriol.*P < 0.05 versus pre-treatment values in each group. For the full 12months of treatment, levels were greater in i.p. than in p.o.; P < 0.0001 for total calcium and P < 0.001 for ionized calcium by multiple regression analysis. Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Serum phosphorus levels during 12months of treatment with intermittent doses of i.p. or p.o. calcitriol.*P < 0.05 versus pre-treatment values in each group. For the 12months of treatment, values were greater in p.o. (□) than in i.p. (•), P < 0.001 by multiple regression analysis. Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 Serum PTH (A) and alkaline phosphatase levels (B) during 12months of treatment with intermittent doses of i.p. (•) or p.o. (□) calcitriol. *P < 0.05 versus pre-treatment values in each group. For the 12months of treatment, values were greater in i.p. than in p.o.; P < 0.001 for PTH and P < 0.001 for alkaline phosphatase by multiple regression analysis. Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 4 The serum levels of 1,25-dihydroxyvitamin D (A) and the average thrice weekly dose of calcitriol (B) during 12months of treatment with intermittent doses of i.p. (▪) or p.o. (○). *P < 0.05 versus pre-treatment value for each group. Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 5 The histological sub-types of renal osteodystrophy before and after 12months of intermittent i.p. (A) or p.o. (B). Abbreviations are: OF, osteitis fibrosa; mild, mild secondary hyperparathyroidism; normal, bone formation rate within the normal range2. Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 907-914DOI: (10. 1046/j. 1523-1755. 1998 Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 907-914DOI: (10. 1046/j. 1523-1755. 1998 Kidney International 1998 54, 907-914DOI: (10.1046/j.1523-1755.1998.00045.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.